Virulizin bovine extract that stimulates macrophages to release cytokines at the tumor data

Results of IMUTF's 22-patient Phase II trial showed disease stabilization for more than three months in six patients, with one surviving 24 months, and one still alive.

The report, to appear in the February issue of the Canadian Journal of Clinical and Investigative Medicine, gave median survival of the group as eight months, whereas the disease typically is fatal within 14 weeks. ...